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Background: The objectives of the study were to elucidate the gender-specific distribution of mefloquine in cellular
and fluid blood compartments when given at therapeutic dosage, to assess its correlation with the occurrence of
treatment-related adverse events, and to explore the necessity of adjusting treatment guidelines for females.
Methods: The distribution of mefloquine following the administration of standard therapeutic doses (1,250 mg
mefloquine in split dose) to 22 healthy Caucasian volunteers was assessed in whole blood, serum, plasma, red
blood cells (RBCs), white blood cells, and platelets using high performance liquid chromatography.
Results: Plasma mefloquine concentrations after 14 hours were considerably higher in female subjects than in
males (2,778 vs 1,017 ng/ml at H14), concordant with a significantly higher frequency, duration, and severity of
adverse reactions. However, mean drug concentrations of RBC appeared slightly higher in male volunteers
(857 vs 719 ng/ml). At H48, a similar situation prevailed, and at H168 the mefloquine concentrations in plasma
continued to be higher in females compared to males (1,353 vs 666 ng/ml), while the concentrations of RBC were
similar in females (389 vs 375 ng/ml). Since the observations relate to healthy individuals, they do not take into
account selective uptake of mefloquine by Plasmodium-infected erythrocytes as in the case of therapeutic drug use.
Conclusion: Although plasma mefloquine concentrations in female healthy volunteers are considerably higher and
the concentrations of the RBCs are initially lower compared to males, they do not seem to justify an adjustment of
treatment guidelines for mefloquine in female Caucasian individuals.
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With the emergence and spread of multi-drug resistance
Plasmodium falciparum, mefloquine is currently being
used as a combination partner with artesunate in the
artemisinin-based combination therapy (ACT). Meflo-
quine resistance and the resultant drop in malaria cure
rates in Southeast Asia has necessitated increases in the
administered mefloquine from 15 mg/kg as a single dose
to 25 mg/kg in split dose, and also in combination with
artesunate treatment [1]. The apparent incidence of ad-
verse events (AEs) following the oral administration of* Correspondence: kesaratmu@yahoo.com
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article, unless otherwise stated.mefloquine is high, with reports of 47 to 90% of adults
experiencing some type of AEs [2-4]. The use of high
doses of mefloquine is also associated with higher fre-
quencies of AEs, particularly in female patients [1,5,6].
Mefloquine [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-
piperidyl)methanol) was discovered by the Walter
Reed Army Institute of Research in the 1970s. Meflo-
quine is a synthetic quinine analogue. The anti-malarial
effects of mefloquine are believed to be due to its accumu-
lation within the parasite’s food vacuole where it interacts
with haem. In this way, the formation of the haemozoin
polymer is prevented and the subsequent drug-haem
complex confers toxicity towards malaria parasites [2].
Mefloquine also inhibits acetylcholinesterase and butyryl-
cholinesterase, the likely cause for the frequentntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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which occur at high dosages of the drug [7]. As
mefloquine hydrochloride is rapidly absorbed by the
gastrointestinal (GI) tract, leading to a sudden onset of
side effects, it is manufactured as a number of different
formulations geared towards slower absorption in the GI
tract. Considerable differences in mefloquine bioavailabil-
ity have been reported for the various formulations [8,9].
Following oral administration of Lariam® tablets, approxi-
mately 75-80% of the drug is absorbed, and time-to-
maximum concentration (tmax) values were found to be
2 to 12 hours. There is little pre-systemic metabolism of
the compound, which has a plasma half-life of 15 to
33 days, with a mean of 21.4 days [10]. Mefloquine is
quickly distributed throughout the body, and has a high
affinity for lipids. In blood plasma, mefloquine is substan-
tially protein-bound. The majority of mefloquine is metab-
olized by the liver to produce carboxy-mefloquine, which
has no anti-malarial activity and a toxicity and half-life
similar to the parent molecule [11]. Despite being highly
soluble, well distributed, and extensively tissue binding,
reports of substantial binding of mefloquine to plasma
proteins in volunteers and patients has also been docu-
mented [12].
The gender-specific differences in the frequency and
severity of AEs experienced following the administration
of mefloquine in prophylactic as well as therapeutic
dosages may at least in part be attributable to different
distribution patterns in liquid and cellular blood com-
partments. Therefore, the aim of the present study was
to elucidate the gender-specific distribution of meflo-
quine in these compartments at therapeutic dosages of
the drug in order to assess any relationship with the
occurrence of treatment-related AEs. Furthermore, the
eventual necessity of adjusting treatment guidelines in
female patients was explored.
Methods
Subjects
This study was conducted with 22 healthy Caucasian
volunteers (10 males, 12 females) aged 20 to 45 years
(median age of 26) at the Institute of Specific Prophylaxis
and Tropical Medicine, Medical University of Vienna.
Written informed consent was obtained from all study
participants and the study protocol was approved by the
ethical review board at the University of Vienna.
Clinical and laboratory investigations
Physical examinations, blood chemistry (including com-
plete blood counts (CBCs)), urinalysis and pregnancy tests
were performed upon enrolment. Those reporting chronic
medical (including neuropsychiatric) disorders or me-
floquine intolerance were excluded from the study, in
addition to those who were heavy smokers or pregnant.CBCs were conducted at 14, 48, and 168 hours after the
administration of the first mefloquine dose. Urinalysis,
biochemistry analysis and complete physical examinations
were repeated 168 hours after drug administration. All
volunteers were monitored for AEs during the 21 days
after the first dose had been administered. During the
entire period the volunteers followed their normal daily
activities.
Drug administration
All subjects received 1,250 mg Lariam® each (five tablets,
250 mg mefloquine hydrochloride per tablet; Hoffmann-la
Roche Pharmaceuticals, Basel, Switzerland) as split dosa-
ges of 750 mg (three tablets) followed by another 500 mg
(two tablets) six hours later.
Blood collection
Venous blood samples were collected in sterile glass
containers at 0 hours (immediately prior to drug admin-
istration), 14 hours (the estimated time to reach peak
plasma concentrations, eight hours after the administra-
tion of the second mefloquine dose), 48 hours (estimated
to be the beginning of the log-linear elimination phase),
and 168 hours (the minimum time required for thera-
peutic drug levels to eliminate malaria parasites).
Whole blood samples were processed immediately by
separating into six fractions (whole blood, plasma, serum,
red blood cells (RBC), white blood cells (WBC), and plate-
lets). This was done using both standard centrifugation
methods as well as the use of Percoll® (Amersham Bio-
sciences, Buckinghamshire, UK) gradient centrifugation
which utilizes colloidal silica coated with polyvinylpyrroli-
done (at gradients 1.059 for platelets and 1.089 for leuko-
cytes). To prevent mefloquine adhesion to plastic surfaces,
all samples were stored in glass containers at ≤ −30°C until
further analysis.
Drug analysis
Mefloquine concentrations were measured at the Pharma-
cology and Toxicology Unit, Chulaborn International
College of Medicine, Thammasat University, Thailand,
using high performance liquid chromatography (HPLC)
with a Microbondapak C18 (4.6 × 250 mm, particle size
5 μm), reverse-phase column and UV-detection at
222 nm [13]. The limit of quantification (LOQ) for
the mefloquine assay is 2 ng/ml. Drug concentrations
were determined for whole blood, serum, plasma, RBCs,
WBCs, and platelets.
Statistical analysis
The student t-test and the one way analysis of variance
(ANOVA) were used to ascertain significant differences
between group means. Correlations between two quanti-
tative variables were investigated by means of Spearman
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used for data not conforming to normal distribution.
The level of statistical significance was set at α = 0.05
for all tests.
Results
The groups of male and female study participants were
comparable in age (mean age 27.6 vs 26.6 years) with simi-
lar social backgrounds and prior exposure to anti-malarials.
The mean total doses per kg of mefloquine received by
the participants were 17.7 (range 13.89-20.83) and 20.7
(16.89-22.73) mg/kg for healthy male (mean weight
71.4 kg) and female (61.2 kg) volunteers, respectively.
Table 1 shows the mefloquine concentrations in whole
blood, serum, plasma, RBCs, WBCs, and platelets from
male and female subjects. Following the first dose, drug
concentrations in whole blood in females reached
1,360 ng/ml at 14 hours to rise to 1,437 ng/ml at
48 hours, whereas male levels decreased moderately
from 1,648 to 1,272 ng/ml. At 168 hours, the drug in
both males and females had decreased to approximately
the same concentration in whole blood (896 ng/ml in
females vs 885 ng/ml in males). A significant difference
(p < 0.001) between plasma concentrations in male
(1,017 ng/ml) and female subjects (2,778 ng/ml) was
found at 14 hours, whereas the concentration in whole
blood was similar for both genders. While RBC drug
concentrations were initially higher in male subjects,
WBC and platelets levels were very similar. However,
the gender differences in mefloquine concentrations in
these cellular compartments were not found to be
significant. RBC mefloquine levels were considerably
lower than in whole blood or serum (p < 0.001), whereas
platelet and WBC mefloquine levels were approximately
six times higher and 20 times higher than in whole
blood, respectively (both p < 0.001). Mean levels in
serum of females were lower than in plasma, whereas
they were higher in males at H14 and H168.. However,
there were no significant gender differences (p > 0.05).
No correlation (p > 0.05) was seen between plasma drugTable 1 Mean mefloquine concentrations, in ng/ml, in
male (n = 10) and female (n = 12) healthy volunteers at
14 hours (H14), 48 hours (H48) and 168 hours (H168)
after administration of the first drug dose
Blood H 14 H 48 H 168
Female Male Female Male Female Male
Whole blood 1,360 1,648 1,437 1,272 896 885
Serum 1,570 1,623 1,244 847 811 1,304
Plasma 2,778 1,017 2,106 1,214 1,353 666
RBC 719 857 633 827 389 375
WBC 35,641 33,885 32,414 29,447 17,584 16,214
Platelets 9,212 9,002 9,710 7,825 5,538 5,808concentrations and RBC levels, suggesting that plasma
levels are a poor predictor of RBC drug levels.
RBC mefloquine concentrations in both males and
females and plasma mefloquine concentrations in males
showed only slight changes between 14 and 48 hours.
Plasma mefloquine concentrations in females, however,
contrasted markedly with the other samples (Table 2).
Concentrations of the drug in the plasma samples from
females were much higher at 14 hours, and although a
decrease occurred during the next 32 hours, concentra-
tions of the drug were considerably higher than those of
the other samples at each of the remaining time points.
All 22 subjects reported drug-related AEs. The most
commonly reported AEs were vertigo (96%), followed by
nausea (82%), headache (73%), sleeping disturbances
(59%), and diarrhoea (41%). The overall symptom scores
(OSS) reflecting the frequency, duration and severity of
drug-related AEs were significantly higher in female
subjects (20.8 in males vs 43.3 in females; p = 0.003).
Frequency, duration and severity of AEs were directly
correlated (r = 0.519; p = 0.016) with plasma drug con-
centrations (Figure 1). No such correlation was found
for drug concentrations in RBCs, WBCs and platelets
(p > 0.05).
Discussion
Previous studies with mefloquine have shown that a
significantly higher frequency and severity of treatment-
and prophylaxis-related AEs occur in female patients
[14-16]. Schwartz et al. [14] hypothesized that if AEs of
mefloquine were related to blood concentrations, drug
monitoring could minimize any untoward effects of the
drug. However, these researchers were unable to find
any gender-related differences in serum mefloquine
concentrations. Kollaritsch et al. [6] reported a signifi-
cantly higher Cmax with female plasma concentrations
and higher incidences of AEs, subsequently recommend-
ing an adjustment of dose regimens in female meflo-
quine recipients.
The present study shows a distinct correlation between
mefloquine plasma concentrations and the severity, dur-
ation and frequency of AEs. Higher mefloquine dosages,
leading to elevated plasma concentrations, are generally
considered to be the most influential parameter in the
pharmacodynamic properties of a drug. AEs also generally
coincide with high blood compartment drug concentra-
tions [1,14]. However, the most important pharmacological
parameter in terms of drug efficacy is the intra-erythrocytic
drug concentration, since the erythrocyte cytoplasm is the
target for malaria parasites. In pharmacokinetic studies,
plasma or serum levels are typically the only parameters
that are measured. Previous data suggest that although
plasma concentrations are significantly higher in females,
their RBC drug concentrations at H14 and H48 are even
Table 2 Gender-specific statistical comparison of mean mefloquine concentrations in plasma and red blood cells
(ng/ml), and of mean plasma/red blood cell ratios
Time Plasma RBC Mean Plasma/RBC
Female Male p* Female Male p* Female/Male p*
H 14 2,778 1,017 < 0.001 719 857 > 0.05 3.51 <0.01
H 48 2,106 1,214 < 0.05 633 827 >0.05 2.84 <0.05
H 168 1,353 666 < 0.05 389 375 >0.05 2.75 >0.05
*Student t-test.
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site of malarial infection, this may be interpreted as a po-
tential shortfall of therapeutic activity [17]. However, previ-
ous investigationshave shown that erythrocytes infected
with P. falciparum contain over four times as much meflo-
quine as compared to non-infected RBC, a phenomenon
similar to the selective uptake of chloroquine by parasitized
erythrocytes [18,19]. These observations would also explain
the equivalence of the therapeutic efficacy of mefloquine in
uncomplicated infections with mefloquine-sensitive P. fal-
ciparum in both genders.
The lack of any significant correlation between plasma
and erythrocytic drug concentrations suggests that
mefloquine plasma levels may not truly represent the
amount of drug reaching uninfected or parasitized RBCs.
However, this would also mean that low plasma concen-
trations, as observed in predominantly male populations,
do not automatically indicate sub-therapeutic erythro-
cytic drug concentrations [20].
The yardstick used in assessing therapeutic drug
regimens of mefloquine in the ACT is the threshold of
therapeutic efficacy. This is obviously not a staticFigure 1 Scatter plot and regression line for mefloquine plasma conc
duration and severity of adverse events (represented by OSS) exhibited sig
r = 0.519; p = 0.016).parameter since it is likely to vary with the sensitivity of
the malaria parasite. The plasma concentrations that
have generally been considered as prophylactic or thera-
peutic in the past seem now to require reassessment.
The lack of a correlation between plasma and erythro-
cytic drug concentrations points in the same direction.
However, in view of the selective uptake of mefloquine
by infected erythrocytes, the significance of mefloquine
bound to uninfected RBC becomes questionable. Thus,
the reported prophylactic threshold of 400 ng meflo-
quine per ml [21] or 567 ng/ml (1.5 μM/l) [22] in
plasma seems to apply to situations where P. falciparum
is not resistant to the drug, indicating that enough mef-
loquine reaches the parasites to kill them by this form of
suppressive prophylaxis. It is noted that mefloquine is
curently being used as a combination partner with arte-
sunate in the artemisinin-based combination therapy
(ACT). This is in contrast to its use as a prophylactic
where adverse effects are rather more relevant as the
drug is being given to a health individual.
The most commonly reported AEs were vertigo, nau-
sea, headache, sleep disturbances, and diarrhoea, with aentrations (ng/ml) and overall symptom score. The frequency,
nificant correlation with mefloquine plasma levels (y = 0.0085x + 16.465,
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drug-related AEs in women. These findings confirm
previous observations in healthy adults [23]. Far fewer AEs
are generally reported from clinical studies in falciparum
malaria patients. The similarity between symptoms of
malaria and some common drug-induced AEs may be the
cause of this phenomenon [2]. In addition, the most
frequent central nervous system-related AE, vertigo, may
be less frequently noticed by patients confined to bed-rest.
Mefloquine concentrations were much higher in WBCs
and platelets, suggesting an active uptake of the drug into
these cells. However, these levels appear to have little
relevance for the treatment of malaria. The considerable
differences between concentrations in plasma and serum
levels may indicate the involvement of differential binding
to specific proteins in the distribution of mefloquine, eg,
fibrinogen [12]. In a previous study in healthy subjects
however, mefloquine concentration was found to be
higher in serum compared to whole blood [24].
Conclusions
The higher AE frequencies and severities caused by
higher plasma concentrations in females in combination
with lower RBC drug concentrations create speculation
about the risks and benefits of mefloquine treatment for
female patients. In spite of the considerably higher num-
ber of AEs in females, a down-adjustment of mefloquine
treatment guidelines for these individuals is not recom-
mended. The observations should stimulate investigations
of the mefloquine dynamics within the first compartment,
especially movement between plasma and erythrocytes in
normal blood and blood infected with P. falciparum. In
this context it would also be important to determine the
location of mefloquine on the surface and within unin-
fected and infected erythrocytes, complemented by a
study of the relevant transport mechanisms.
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